Get the Stockscreener App
22.51
11.38%
-2.89
First Tracks Biotherapeutics Inc stock is traded at $22.51, with a volume of 30,777.
It is down -11.38% in the last 24 hours and up +0.00% over the past month.
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
See More
Previous Close:
$25.40
Open:
$25.79
24h Volume:
30,777
Relative Volume:
36.49
Market Cap:
$782.20M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-4.21%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$22.50
$26.80
1-Week Range:
$22.50
$26.80
52-Week Range:
$19.00
$26.80
First Tracks Biotherapeutics Inc Stock (TRAXV) Company Profile
Name
First Tracks Biotherapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare TRAXV vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRAXV
First Tracks Biotherapeutics Inc
|
22.51 | 782.20M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
441.20 | 112.22B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
750.57 | 79.35B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
849.04 | 52.80B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.66 | 41.32B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
323.87 | 35.95B | 5.36B | 287.73M | 924.18M | 2.5229 |
First Tracks Biotherapeutics Inc Stock (TRAXV) Latest News
TRAXV|TRAXV.NB|Price:24.550| - TradingKey
First Tracks Biotherapeutics, Inc. (TRAXV) - Minichart
TRAXV Price Today: First Tracks Biotherapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Anaptys to spin-off First Tracks Biotherapeutics, announces $100M buyback - MSN
TRAXV: Static price chart | First Tracks Biotherapeutics, Inc. | US3371851029 - marketscreener.com
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Market Today: JPM's Dimon warns; UAL hikes fees; NBIX buys SLNO - GuruFocus
Spin-off Imminent At AnaptysBio - San Diego Business Journal
symbol__ Stock Quote Price and Forecast - CNN
First Tracks Biotherapeutics to be spun off from AnaptysBio, Nasdaq trading set for April 20 - Investing.com
ANAPTYSBIO (ANAB) reports ownership of 100 First Tracks Biotherapeutics shares - Stock Titan
First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement - marketscreener.com
AnaptysBio authorizes $100M stock buyback, plans spin-off By Investing.com - Investing.com Australia
AnaptysBio appoints Susannah Gray to board; Dennis Mulroy and Eric Loumeau to Separate - TradingView — Track All Markets
Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update - Sahm
AnaptysBio Plans First Tracks Spin-Off as Jemperli Royalties Surge, Buybacks Possible - Yahoo Finance
Assessing AnaptysBio (ANAB) Valuation After Profitability Turnaround And Strong Jemperli Royalty Progress - Yahoo Finance
GSK's Biopharma Collaborations Highlighted in AnaptysBio Spin-Of - GuruFocus
Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma - Yahoo Finance
Press Release Service: Capsida Receives FDA Fast Track Designation for Its Potential First-in-Class IV-Administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy - CRISPR Medicine News
Fresh Tracks to cease stock trading as drug company dissolves - BizWest
Fresh Tracks Therapeutics Announces Dissolution, Initial Cash Distribution and Termination of Trading on the OTC Pink Market - Yahoo Finance
Fresh Tracks expects to distribute $5M to $7M to shareholders after dissolution - Daily Camera
Cash-strapped Fresh Tracks pauses R&D run as search for a buyer continues - Fierce Biotech
Fresh Tracks Announces $8.25 Million Buyout of Its Right to Receive Future Sofpironium Bromide Payments from Botanix - Yahoo Finance
Excision BioTherapeutics receives FDA Fast Track designation for EBT-101, a first-in-class CRISPR-based gene therapy candidate to functionally cure HIV-1 - European AIDS Treatment Group
Fresh Tracks may disappear as biotech mulls sale to continue autoimmune pipeline - Fierce Biotech
Fresh Tracks Therapeutics (FRTX) Stock Price, News & Analysis $FRTX - MarketBeat
Brickell Biotech Announces Corporate Rebranding to Fresh Tracks Therapeutics - GlobeNewswire
First Tracks Biotherapeutics Inc Stock (TRAXV) Financials Data
There is no financial data for First Tracks Biotherapeutics Inc (TRAXV). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.19%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):